What is the market's earnings forecast for Lifeward next quarter?

What were the key takeaways from Lifeward's earnings call?

What does Lifeward do and what are its main business segments?

What is Lifeward's gross profit margin?

What is Lifeward's latest dividend and current dividend yield?

What were the key takeaways from Lifeward’s earnings call?

What guidance did Lifeward's management provide for the next earnings period?

What factors drove the changes in Lifeward's revenue and profit?

- **Strategic Expansion**: $10M Oramed partnership for oral insulin and $10M Skelable acquisition for AI exoskeletons.
- **Operational Efficiency**: 25% cost reduction, 22% ReWalk unit growth, and 23% cash usage decline.
- **Pipeline Momentum**: 104 U.S. ReWalk leads, 26 AlterG backlog, and 18-24M exoskeleton launch timeline.
- **Financial Resilience**: $16.8M cash usage vs. $21.7M prior year, $3M Oramed loan secured.


**【CEO Opening Remarks】**
- Announced strategic partnership with Oramed, pending shareholder approval, to access $10M convertible note and expand into oral insulin market with ORMP-0801.
- Highlighted Skelable acquisition for AI-powered upper extremity exoskeleton, targeting 245,000 annual stroke survivors in the U.S.
- Emphasized focus on cash flow positivity and disciplined capital allocation.

**【CFO Financial Commentary】**
- Full year 2025 revenue $22M (-14% YoY), driven by 22% unit growth in ReWalk despite $12.9M (-18%) decline in AlterG sales.
- Gross margin improved to 38.2% (32% in 2024), operating expenses down 25% to $28.1M.
- Operating cash usage reduced 23% to $16.8M, with $3M loan from Oramed and $10M convertible note pending.

**【Q&A Highlights】**
- **Oramed Technology**: Fully funded clinical trial for ORMP-0801; expects safety/bench studies, no need for large-scale trials. Leverage existing commercial infrastructure post-approval.
- **Upper Extremity System**: 18-24 month timeline for FDA 510(k) clearance; targeting 2026 launch with minimal clinical requirements.
- **Market Strategy**: Diversified portfolio of medtech and biotech to mitigate risk; focus on reimbursement, channel partnerships, and operational efficiency.
- **Pipeline Growth**: 104 U.S. ReWalk leads, 49 Germany leads (22 active rentals), and 26 AlterG backlog systems.


Lifeward Ltd.(LFWD)-20260318-2025 Q4 Earnings call transcript

**Key Takeaways:**
- **Revenue Growth**: Q3 revenue up 8% QoQ, driven by Medicare ReWalk sales, with 2025 guidance reaffirmed at $24-26M.
- **Margin Expansion**: Gross margin improved to 43.7%, operating loss down 27% YoY, signaling efficiency gains.
- **European Expansion**: CE-marked ReWalk 7 targets 40% of global exoskeleton market, with 33 active German rentals.
- **Financial Resilience**: $3M loan bolsters liquidity, with cash to fund operations into Q1 2026.
- **Strategic Shifts**: Sales force restructuring and channel partnerships aim to unlock AlterG growth and neuro rehab market share.

**【CEO Summary Section】**
- **Operational Transformation**: CEO Mark Grant highlights a 16% reduction in quarterly cash burn and 27% decline in non-GAAP operating loss YoY, driven by streamlined operations and cost efficiencies.
- **Market Expansion**: Secured first Medicare Advantage revenue for ReWalk 7 and expanded into Europe with CE mark approval, targeting 40% of global exoskeleton opportunity.
- **Financial Strength**: Completed a $3M loan with Oramed, enhancing liquidity and supporting transformation efforts.

**【CFO Financial Commentary】**
- **Revenue Performance**: Q3 2025 revenue $6.2M (+1.1% YoY, +8% QoQ), with ReWalk product line contributing $2.9M (50% from Medicare).
- **Profitability**: Gross margin improved to 43.7% (vs. 36.2% YoY), driven by lower production costs post-manufacturing consolidation.
- **Efficiency Gains**: Non-GAAP operating expenses down 15% YoY to $5.7M, reflecting reduced R&D spend and streamlined marketing/sales.
- **Liquidity**: $2M cash post-loan, supporting operations into Q1 2026.

**【Q&A Highlights】**
- **ReWalk Momentum**: 15 units delivered Q3 vs. 4 YoY, with 117 U.S. leads and 33 Germany rentals (3-6mo conversion rate).
- **AlterG Strategy**: Restructured sales teams to focus on capital sales and neuro rehab, aiming to stabilize and grow AlterG revenue.
- **Guidance Confidence**: Q4 typically strongest quarter; $24-26M 2025 guidance supported by backlog and pipeline strength.
- **Partnership Impact**: CorLife collaboration growing pipeline, with 20+ beta programs underway.
- **Global Ambitions**: Eyeing 40% European market share, with CE-marked ReWalk 7 targeting worker's comp and broader rehab use cases.

Lifeward Ltd. (LFWD) Q3 2025 Earnings Call Transcript

- **Record Medicare Placements**: Q2 2025 saw the highest ReWalk 7 unit installations (20 systems) in the U.S., with 130+ qualified leads in the pipeline.
- **Operational Efficiency**: Cash burn reduced to $3.9M (down 30% YoY), driven by in-house manufacturing and facility closures.
- **Updated Guidance**: 2025 revenue forecast of $24-26M reflects cautious near-term outlook but maintains long-term growth potential.
- **Germany as Growth Model**: Profitable operations and innovative business models in Germany highlight scalable strategies for global expansion.

**【Management Opening Remarks】**
- CFO Almog Adar emphasized forward-looking statements and reminded listeners of the risks involved in future projections. He highlighted the company's commitment to transparency and the availability of updated information on their website.

**【CEO Summary Section】**
- **Revenue Performance**: Q2 2025 revenue was $5.7 million, down 11% YoY but up 14% QoQ, driven by higher sales in Germany. ReWalk Medicare placements reached a record high, with 20 ReWalk 7 units installed in the U.S.
- **Product Innovation**: ReWalk 7 features improved accessibility, battery life, and cloud connectivity. The company is awaiting CE clearance for Europe and has seen strong therapist and patient feedback.
- **Operational Efficiency**: Transition to in-house manufacturing reduced costs and improved quality. Closure of the AlterG facility and streamlined processes reduced cash burn to $3.9 million (down from $5.6 million YoY).
- **Growth Strategy**: Focused on three pillars—commercial adoption, portfolio diversification, and operational excellence. Germany is a key market with profitable operations and innovative business models.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: Traditional products ($2.5M) declined 19% YoY due to one-time Medicare revenue in Q2 2024. AlterG ($3.2M) decreased 11% YoY due to international timing delays.
- **Gross Profit**: GAAP gross profit was $2.5M (43.9% of revenue), with non-GAAP margin at 44% due to one-time items.
- **Operating Expenses**: GAAP expenses rose 26% YoY to $9.1M due to a $2.8M goodwill impairment charge. Non-GAAP expenses fell 13% to $6M, reflecting cost-saving measures.
- **Cash Position**: Ended Q2 with $5.1M in cash, down from $5.5M in Q1, with usage driven by slower Medicare collections and inventory buildup.
- **2025 Guidance**: Updated to $24-26M revenue and $12-14M non-GAAP net loss, reflecting cautious near-term outlook.

**【Q&A Key Highlights】**
- **Medicare Revenue**: Q2 2025 saw the highest unit placements since April 2024, with 130+ qualified leads in the U.S. pipeline.
- **Tariff Impact**: ReWalk is exempt as a medical device, but AlterG faces potential tariffs with China/Taiwan. Solutions are being explored.
- **ReWalk 7 Pricing**: Medicare reimbursement remains unchanged, but private payers may vary. Long-term focus is on expanding access before adjusting pricing.
- **AlterG Growth**: Channel partnerships and sports market focus expected to drive sustained growth, with Q2 sales up 14% QoQ.
- **Guidance Adjustment**: Lowered expectations reflect slower payer approvals and extended revenue cycles, but pipeline strength supports long-term growth.
- **Inventory Management**: Transition to in-house manufacturing caused short-term margin pressure, but quality and cost improvements are expected.


ReWalk Robotics (LFWD)-14 Aug 25-2025 Q2 Earnings call transcript

- **Revenue Momentum**: Q1 2025 revenue of $5M reflects 12% growth on adjusted basis, with 10 ReWalk units placed in Medicare. 
- **Pipeline Strength**: 120+ U.S. ReWalk leads (+70% in 2Q) and 36 active rentals in Germany. 
- **Cost Efficiency**: 25% Q1 operating loss reduction; $1M adj. loss target for Q4 2025. 
- **Product Innovation**: ReWalk 7 features crutch control and longer battery life; AlterG NEO drives 19% QoQ growth. 
- **Market Expansion**: CorLife partnership taps 6-7% of U.S. workers' comp market; BARMER contract sets precedent in Germany. 
- **Payment Cycle Improvement**: CMS MACs aim to reduce claim processing from 12-18 months to 6-9 months. 


**【CEO Opening Remarks】**
- **Revenue Growth & Pipeline**: Q1 2025 revenue of $5M (down 6% YoY, but +12% on adjusted basis). Over 120 qualified ReWalk leads in the U.S. pipeline (+70% in 2Q), 36 active rentals in Germany, and 19% growth in AlterG sales. 
- **Cost Efficiency**: 25% reduction in Q1 operating loss; expect accelerating savings from facility closures and streamlined operations. 
- **Leadership Transition**: CEO Larry Jasinski to retire mid-2025, with transition plans underway. 

**【CFO Financial Breakdown】**
- **Revenue by Product**: ReWalk sales ($1.6M) up 10 units placed in Medicare; AlterG ($3.4M) constrained by supply but +19% YoY. 
- **Gross Margin**: 42.2% (GAAP) vs. 26.4% YoY, driven by higher-margin ReWalk sales. 
- **Operating Expenses**: $7M (GAAP) down 11% YoY; $6.7M non-GAAP down 8%. 
- **Cash Position**: $5.7M at end of Q1, +$500K raised post-quarter. 

**【Q&A Highlights】**
- **Tariff Impact**: Minimal exposure (ReWalk produced in Israel, AlterG NEO in China). 
- **2025 Guidance**: $28-30M revenue; Q4 adj. operating loss ~$1M. 
- **ReWalk 7 Launch**: First commercial sale with top-10 insurer; features easier usability, longer battery life. 
- **CorLife Partnership**: Expands access to workers' comp patients (6-7% of market). 
- **BARMER Contract**: Germany's first comprehensive exoskeleton insurance agreement, including system replenishment. 
- **AlterG NEO Growth**: 19% QoQ growth; 27 units in backlog. 
- **MACs Streamlining**: Uniform claim criteria expected to reduce payment cycles from 12-18 months to 6-9 months. 


Lifeward Ltd. (LFWD) Q1 2025 Earnings Call Transcript

- **Revenue Growth**: 85% YoY to $25.7M, Q4 record $7.5M
- **Strategic Wins**: CMS $91K ReWalk pricing, BARMER Germany contract, Hungary coverage
- **2025 Outlook**: $28-30M revenue, Q4 op loss ≤$1M
- **Key Initiatives**: CorLife worker's comp partnership, MyoCycle home market expansion, AlterG national accounts
- **Financial Health**: $11.7M cash post-Q4, 2025 op loss reduction plan

**【CEO Summary Section】**
- **2024 Key Achievements**: Established CMS lump sum payment, $91,032 CMS price for ReWalk, BARMER contract in Germany, Hungary coverage expansion, 85% YoY revenue growth to $25.7M, Q4 record $7.5M revenue.
- **2025 Strategic Focus**: 
  - Maintain growth while reducing Q4 2025 operating loss ≤$1M
  - Target workers' comp (lower processing costs), MyoCycle (improved margins), AlterG national accounts
  - Product mix optimization, COGS reduction, tight expense controls

**【CFO Financial Commentary】**
- **Q4 2024 Results**: 
  - Revenue: $7.5M (8.7% YoY), ReWalk $2.0M, AlterG $5.5M
  - Gross Margin: GAAP 24.4%, Non-GAAP 45.4%
  - Operating Expenses: GAAP $17.1M (impairment charge), Non-GAAP $6.7M
  - Cash: $6.7M + $5M post-quarter financing
- **2025 Guidance**: 
  - Revenue $28-30M, Non-GAAP Op Loss $7-9M
  - Gross Margin 47-49%, Op Ex $22-23M
  - Sequentially improving Q1-Q4 performance

**【Q&A Key Takeaways】**
- **CorLife Partnership**: Streamlines worker's comp claims processing, 30-45 day payment cycle, 6% spinal cord injury market access
- **ReWalk 7 Launch**: FDA submission complete, expected H1 2025 clearance
- **MyoCycle Expansion**: Home use market 4x clinic size, expanded distribution rights
- **Efficiency Gains**: Reduced headcount (35%), merged operations, R&D completion
- **Capital Strategy**: ATM facility, non-dilutive financing options to address $6.7M cash balance concern

Actual										-31.08	-18.48	-15.12	-11.76	-6.72	-5.88	-5.04	-5.04	-5.88	-5.88	-7.56	-7.56	-5.88	-6.72	-10.92	-10.92	-8.76	-6	-4.2	-20.76	-5.28	-3.72	-2.28	-2.85
Forecast										-21.84	-22.68	-13.44	-11.76	-5.88	-5.04	-5.04	-3.36	-4.2	-3.36	-5.04	-5.88	-6.72	-5.88	-9.24	-9.24	-8.4	-6.6	-3.78	-6.52	-3.96	-3.42	-2.4	-0.96
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-42.31%	+18.52%	-12.50%	0.00%	-14.29%	-16.67%	0.00%	-50.00%	-40.00%	-75.00%	-50.00%	-28.57%	+12.50%	-14.29%	-18.18%	-18.18%	-4.29%	+9.09%	-11.11%	-218.40%	-33.33%	-8.77%	+5.00%	-196.88%

Actual	--	--	--	--	--	--	--	--	--	760.00K	1.67M	747.00K	1.22M	1.32M	1.44M	1.97M	1.24M	876.00K	1.57M	886.00K	2.18M	1.23M	1.34M	4.40M	6.88M	5.28M	6.71M	6.13M	7.54M	5.03M	5.72M	6.20M	5.08M
Forecast	--	--	--	--	--	--	--	--	--	2.20M	778.00K	1.09M	1.50M	1.00M	1.41M	1.60M	1.78M	2.20M	2.32M	1.82M	2.05M	2.00M	1.30M	4.28M	7.23M	5.50M	6.65M	8.44M	7.84M	5.84M	6.69M	6.31M	7.87M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-65.45%	+114.40%	-31.59%	-19.07%	+31.60%	+1.56%	+23.10%	-30.42%	-60.18%	-32.36%	-51.29%	+6.40%	-38.50%	+2.85%	+2.80%	-4.73%	-3.95%	+0.86%	-27.40%	-3.73%	-13.80%	-14.49%	-1.84%	-35.42%

LFWD

LFWD fundamentals

LFWD Q4 2025 Earnings

Earnings Call

You can ask Aime

LFWD

LFWD fundamentals

LFWD Q4 2025 Earnings

Earnings Call

LFWD Earnings Call Summary for Q4/20258:30 AM on Mar 18, 2026

LFWD Earnings Call Summary for Q3/20258:30 AM on Nov 14, 2025

LFWD Earnings Call Summary for Q2/20258:30 AM on Aug 14, 2025

LFWD Earnings Call Summary for Q1/20258:30 AM on May 15, 2025

LFWD Earnings Call Summary for Q4/20248:30 AM on Mar 7, 2025

You can ask Aime